⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28118230 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL2124558 | 0.77 | CPA1 (0.39) | — | |
| SCHEMBL9229615 | 0.74 | — | — | |
| SCHEMBL18867735 | 0.71 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL8486814 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL8675050 | 0.71 | TP53 (0.44) | — | |
| SCHEMBL28380223 | 0.70 | — | — | |
| SCHEMBL1980632 | 0.67 | — | — | |
| SCHEMBL30520343 | 0.67 | HIF1A (0.35) | — | |
| SCHEMBL9512718 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| CN-116999396-A | Modular compositions for removal of soluble biomolecules and related methods | 纳米提克斯有限责任公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023075766-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023049475-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| EP-4153604-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2023-03-29 | — | — | EP | disclosed |
| EP-4125893-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | Biohaven Therapeutics Ltd. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4061425-A1 | DIRECTED CONJUGATION TECHNOLOGIES | Kleo Pharmaceuticals, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| EP-4022059-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2022-07-06 | — | — | EP | disclosed |
| EP-3993818-A2 | CD38-BINDING AGENTS AND USES THEREOF | Kleo Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021237223-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021071858-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021003050-A2 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-3630199-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018223056-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| EP-2598170-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015681-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |